Breast Cancer — Loss of PTEN Predicts Resistance to Treatment
- 25 November 2004
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (22) , 2337-2338
- https://doi.org/10.1056/nejmcibr043143
Abstract
A new study uncovers a mechanism by which trastuzumab (Herceptin) counters the progression of cancer. The findings point to a subgroup of patients who are likely to have a response to treatment.Keywords
This publication has 5 references indexed in Scilit:
- Intragenic ERBB2 kinase mutations in tumoursNature, 2004
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Pten Dose Dictates Cancer Progression in the ProstatePLoS Biology, 2003
- Overexpression of ErbB2 in cancer and ErbB2-targeting strategiesOncogene, 2000
- The Multiple Roles of PTEN in Tumor SuppressionPublished by Elsevier ,2000